Stockscreener 앱 받기
1.355
2.27%
0.035
시간 외 거래:
1.35
-0.005
-0.37%
전일 마감가:
$1.32
열려 있는:
$1.32
하루 거래량:
615.35K
Relative Volume:
0.72
시가총액:
$98.22M
수익:
-
순이익/손실:
$-44.95M
주가수익비율:
-1.5182
EPS:
-0.8925
순현금흐름:
$-56.37M
1주 성능:
+6.30%
1개월 성능:
+5.47%
6개월 성능:
+1.50%
1년 성능:
-21.97%
1일 변동 폭
$1.30
$1.39
1주일 범위
$1.26
$1.39
52주 변동 폭
$0.8719
$2.99
바이오미아 퓨전 Stock (BMEA) Company Profile
명칭
Biomea Fusion Inc
전화
(650) 980-9099
주소
1599 INDUSTRIAL ROAD, SAN CARLOS
Compare BMEA vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMEA
Biomea Fusion Inc
|
1.355 | 95.68M | 0 | -44.95M | -56.37M | -0.8925 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
바이오미아 퓨전 Stock (BMEA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-13 | 개시 | Rodman & Renshaw | Buy |
| 2025-08-28 | 개시 | Jefferies | Buy |
| 2025-06-03 | 재개 | Piper Sandler | Overweight |
| 2024-10-09 | 개시 | Edward Jones | Buy |
| 2024-09-27 | 업그레이드 | Rodman & Renshaw | Neutral → Buy |
| 2024-09-27 | 업그레이드 | Truist | Hold → Buy |
| 2024-08-29 | 개시 | CapitalOne | Overweight |
| 2024-06-11 | 다운그레이드 | Truist | Buy → Hold |
| 2024-06-07 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-04-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-02-06 | 개시 | Truist | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-06-26 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-12 | 개시 | Barclays | Overweight |
| 2023-03-29 | 재확인 | Oppenheimer | Outperform |
| 2023-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2023-02-24 | 개시 | Citigroup | Buy |
| 2022-06-02 | 재개 | H.C. Wainwright | Buy |
| 2022-01-12 | 개시 | H.C. Wainwright | Buy |
| 2021-12-17 | 개시 | Oppenheimer | Outperform |
| 2021-05-11 | 개시 | JP Morgan | Overweight |
| 2021-05-11 | 개시 | Jefferies | Buy |
| 2021-05-11 | 개시 | Piper Sandler | Overweight |
모두보기
바이오미아 퓨전 주식(BMEA)의 최신 뉴스
Biomea Fusion (NASDAQ:BMEA) Gains Attention As Institutions Expand Exposure - kalkinemedia.com
Biomea Fusion shares new insights on three stages of type 1 diabetes in expert webinar - Traders Union
Biomea Fusion doses first patient in icovamenib-semaglutide study By Investing.com - Investing.com Canada
Biomea Fusion doses first patient in icovamenib-semaglutide study - Investing.com
Biomea Fusion Trial Tests Obesity Drug Combo Beyond Weight Loss - Stock Titan
Renaissance Technologies LLC Grows Position in Biomea Fusion, Inc. $BMEA - MarketBeat
Biomea Fusion Inc (BMEA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
HC Wainwright Expects Stronger Earnings for Biomea Fusion - MarketBeat
Biomea Fusion, Inc. (NASDAQ:BMEA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Biomea Fusion Stock (BMEA) Opinions on Clinical Milestones and Liquidity Concerns - Quiver Quantitative
Icovamenib clinical enrollment opens for type 2 diabetes study, Biomea Fusion initiates - Traders Union
Piper Sandler Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Citizens JMP Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
Biomea Fusion Inc (BMEA) Stock News Today - TradingKey
Biomea Fusion explores new scientific approaches to diabetes treatment - Traders Union
Oppenheimer Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Biomea Fusion, Inc. Stock 12‑Month Price Target Cut to $6.71, Implies 433% Upside - TradingView
Biomea Fusion, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Biomea Fusion (NASDAQ:BMEA) Issues Earnings Results - MarketBeat
Biomea Fusion Q2 loss narrows, cash runway into Q2 2027 - TradingView
Biomea Fusion (NASDAQ: BMEA) trims R&D, discloses going concern risk - Stock Titan
Biomea Fusion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights - Yahoo Finance
BMEA: Net loss narrowed and clinical trial progress supports cash runway into Q2 2027 - TradingView
Biomea Fusion (BMEA) Gains 2.56% to $1.2 as Key Levels Come into FocusStock Surge Alerts - dars.gov.et
Participants sought for type 2 diabetes trial evaluating icovamenib, Biomea Fusion announces - Traders Union
Biomea Fusion Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
BMEA Q2'26 Earnings: EPS estimate is (0.22) USD - tradingview.com
Biomea Fusion (BMEA) to Post Earnings on Tuesday - MarketBeat
Biomea Fusion Inc (BMEA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biomea Fusion Inc (BMEA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BMEA|Biomea Fusion Inc|Price:1.250|Chg%:-0.010 - TradingKey
Biomea Fusion Inc (BMEA) Balance Sheet - TradingKey
Biomea Fusion Inc (BMEA) Income Statement - TradingKey
Biomea Fusion Inc (BMEA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biomea Fusion Inc (BMEA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BMEA|Biomea Fusion Inc|Price:1.265|Chg%:+0.015 - TradingKey
BMEA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
TradingKey - TradingKey
Biomea Fusion Inc (BMEA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biomea Fusion Inc (BMEA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Biomea Fusion Inc (BMEA) Institutional Confidence - TradingKey
Biomea Fusion Market Sentiment - Benzinga España
Biomea Fusion(BMEA) Stock Options Chain | Quotes & News - Moomoo
Biomea Fusion, Inc. Revenue Breakdown – NASDAQ:BMEA - TradingView
Biomea Fusion launches Phase II trial for icovamenib in type 1 diabetes - Traders Union
Biomea Fusion outlines key stages involved in clinical trials for new medicines - Traders Union
BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, - GuruFocus
Biomea Fusion presents Phase II data on icovamenib in type 1 diabetes at ADA meeting - Traders Union
Biomea Fusion Inc Financial Disclosures & SEC Filings - TradingView
Biomea Fusion Inc. (BMEA) Q1 2026 Earnings: Narrower-than-expected loss highlights cost managementDebt Analysis Report - dars.gov.et
바이오미아 퓨전 (BMEA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오미아 퓨전 주식 (BMEA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Hitchcock Michael J.M. | Interim CEO |
Dec 02 '25 |
Buy |
0.99 |
100,000 |
99,180 |
115,000 |
| Erdtmann Rainer M | See Remarks |
Nov 28 '25 |
Buy |
1.10 |
40,000 |
44,052 |
683,027 |
| Erdtmann Rainer M | See Remarks |
Dec 01 '25 |
Buy |
1.05 |
10,000 |
10,500 |
693,027 |
2.67%
0.04%
자본화:
|
볼륨(24시간):